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Background: In the Phase II SYNCHRONY study, aleglitazar significantly increased high-density lipoprotein cholesterol (HDL-C) and reduced 
triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), combined with improving glycemic control in patients with type 2 diabetes 
(T2DM).1 The atherogenic potential of raised TG combined with low HDL-C, even in the presence of normal LDL-C, is becoming recognized.2 This post 
hoc analysis aimed to determine the effect of aleglitazar on TG/HDL-C ratio in patients with T2DM.
Methods: In SYNCHRONY, 332 T2DM patients were randomized to 16 weeks’ once-daily treatment with aleglitazar (150 μg shown here), placebo 
(n=55 in each group), or pioglitazone 45 mg (n=57). This analysis determined least squares mean changes in TG/HDL-C (mg/dL) ratio from baseline 
to study end, assessed using ANCOVA.
Results: Aleglitazar (150 μg) significantly reduced the TG/HDL-C ratio from baseline vs placebo, in both absolute and percent change (Table). 
Quantitatively similar results were seen for aleglitazar 300 μg and 600 μg (not shown) and reductions were consistently numerically greater than 
with pioglitazone. 
Change from baseline in TG/HDL-C ratio at end of 16 weeks’ treatment (ITT,LOCF)
TG/HDL-C (mg/dL) ratio
Placebo
n=54
Aleglitazar (150 μg)
n=54
Pioglitazone (45 mg)
n=57
Baseline value, mean (SE) 5.90 (1.14) 4.91 (0.63) 5.63 (0.92)
Absolute change from baseline, LSmean (95% CI)
-0.27
(-0.99, 0.45)
-2.53
(-3.24, -1.81)
-1.31
(-2.03, -0.59)
Difference from placebo (95% CI)
-2.26
(-3.25, -1.26)
p<0.0001
-1.04
(-2.02, -0.06)
p=0.0381
Percent change from baseline, LSmean (95% CI)
14.3
(1.15, 27.5)
-40.9
(-54.0, -27.9)
-17.5
(-30.7, -4.3)
Difference from placebo (95% CI)
-55.3
(-73.5, -37.1)
p<0.0001
-31.8
(-49.8, -13.8)
p=0.0006
Conclusion: Aleglitazar significantly reduced the TG/HDL-C ratio vs placebo. Favorable effects on the TG/HDL-C ratio can correlate with delayed 
atheroma progression in patients with T2DM,2 therefore aleglitazar may potentially have beneficial effects on atherosclerosis in patients with T2DM.
1Henry Lancet 2009;374:126-35
2Nicholls J Am Coll Cardiol 2011;57:153-9
